Guggenheim Capital LLC Summit Therapeutics Inc. Transaction History
Guggenheim Capital LLC
- $12 Billion
- Q4 2024
A detailed history of Guggenheim Capital LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 42,887 shares of SMMT stock, worth $948,660. This represents 0.01% of its overall portfolio holdings.
Number of Shares
42,887Holding current value
$948,660% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
232Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$540 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$258 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$175 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$145 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$124 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.45B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...